Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Altimmune launches proposed public offering to fund late-stage trial
Altimmune secures $225M to test GLP-1 in liver disease - Washington ...
Altimmune secures $225 million financing for pemvidutide development ...
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny ...
Why is Altimmune stock falling today?
Altimmune Plunges 14.56% on Goldman Sachs Downgrade
Altimmune, Inc: Altimmune Announces CEO Transition and Succession Plan
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To ...
Why Is Altimmune Stock Up Over 10% Before The Bell?
Altimmune - 2025/02/19 | Piper Sandler
Altimmune Soars 13.0% After FDA Breakthrough Tag for Pemvidutide in ...
A Closer Look at Altimmune Inc’s Financial Results and Future Prospects ...
Altimmune Initiates RESTORE Phase 2 Trial for Liver Disease Treatment
Altimmune sees phase 1 success in tricky NASH indication with GLP-1 ...
Altimmune Stock Surges After FDA Breakthrough for MASH Therapy
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in ...
Altimmune Approaches Pivotal Moment with Leadership Shift and Key Data
Altimmune logo in transparent PNG format
Altimmune Stock: Pemvidutide’s 48-Week Data Confirms The Market’s ...
Altimmune Q2 report drives stock rise, pemvidutide promising for ...
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - The Globe ...
Insider Makes Bold Move on Altimmune Stock With Fresh Buy - TipRanks.com
Altimmune Announces Pricing of $75 Million Registered Direct Offering ...
Altimmune touts ‘best-in-class’ lean mass results for weight loss ...
Altimmune bails on hepatitis B after phase 2 data disappoint, quashing ...
Altimmune Initiates RESTORE Phase 2 Trial for Pemvidutide in Alcohol ...
Altimmune Enrolls First Patient in Restore Phase 2 Trial for Alcohol ...
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ ...
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? | Laser ...
Goldman Sachs Initiates Sell Rating for Altimmune Due to Financial ...
Altimmune completes dosing in MOMENTUM trial to treat obesity
Altimmune shares slump as weight-loss drug's fatty liver trial data ...
Altimmune (ALT) Stock Soars 27% on Phase 2 Obesity Drug Data - Wealthy ...
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) | Seeking ...
Altimmune Stock Surges After FDA Breakthrough Therapy Approval
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer ...
Altimmune Shares Rally as FDA Accepts Liver Stiffness as Surrogate ...
Short ALT: Altimmune Inc. faces bearish rejection at major resistance ...
Why Altimmune Stock is Soaring
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb ...
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon ...
Altimmune prices $75M direct stock offering for MASH | ALT Stock News
Altimmune Obesity Drug Provides Class-Leading Lean Mass Preservation ...
Altimmune Shares Poised for Potential Breakthrough - Stocks Today
Altimmune Reveals Pemvidutide's Effects on Cardioinflammatory Lipids at ...
Is Altimmune Inc (ALT) Stock at the Top of the Biotechnology Industry?
Altimmune shares slide after $75 million registered direct offering
Altimmune gets FDA nod to start clinical trials for intranasal Covid-19 ...
Altimmune Announces CEO Transition Plan - TipRanks.com
Altimmune Jumps On Takeover Rumors After Launching Alcohol Use Disorder ...
Altimmune posts mid-stage trial data for MASH drug (ALT:NASDAQ ...
Marker Therapeutics shares rise 3.13% premarket after Altimmune ...
Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves ...
Altimmune Stock: Probing Pemvi's MASH Data (NASDAQ:ALT) | Seeking Alpha
Altimmune put volume heavy and directionally bearish
Altimmune Secures Up to $100MM in Credit Facility from Hercules Capital ...
Altimmune Ends RECLAIM Phase 2 Enrollment Early; 100 Patients | ALT ...
Altimmune Stock: Pemvidutide Shows Promise In MASH; Lacks Competitive ...
Citizens JMP Lowers Altimmune Price Target to $15, Maintains Outperform ...
Altimmune Stock $ALT to Surge in 2024 - Low market cap and waiting for ...
Altimmune obesity drug well-positioned despite safety data - PharmaLive
Positive Topline Results for Altimmune in Obesity Drug Trial; Shares up ...
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on ...
Altimmune Branding Image | Bethesda Headshots
Altimmune Announces FDA Clearance of Single-Dose, Needle-Free ...
UAB, Altimmune Inc. Testing COVID-19 Vaccine
Altimmune Announces FDA Approval for Phase 1 COVID-19 Vaccine Clinical ...
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver ...
Altimmune Lab Portrait 7 | Bethesda Headshots
Altimmune完成2.25亿美元融资用于MASH药物试验 提供者 Investing.com
Altimmune's Breakthrough in Liver Disease Treatment: A Closer Look ...
Altimmune's Pemvidutide Receives FDA Fast Track Status for Alcohol Use ...
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In ...
Altimmune, Inc. shares rise 1.02% intraday after announcing topline ...
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential
Altimmune’s Obesity Drug Candidate Advances with Clear Phase 3 Pathway
Altimmune’s Leadership Shuffle: A Strategic Pivot Ahead of Critical Data
PFG Investments LLC Makes New $96,000 Investment in Altimmune, Inc ...
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to ...
Altimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising ...
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH ...
Class Action Filed Against Altimmune, Inc. (ALT) - October 6, 2025 ...
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT ...
Altimmune's RESTORE TRIAL: A Promising Step in ALD Treatment
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is ...
Altimmune: Deciphering The MASH Crash (Rating Upgrade) (NASDAQ:ALT ...
Altimmune: Pemvidutide Differentiation Advancement In MASH Space ...
Positive week for Altimmune, Inc. (NASDAQ:ALT) institutional investors ...
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The ...
Marketing Mix Analysis of Altimmune, Inc. (ALT) – DCFmodeling.com
Big Changes at Altimmune: A New CEO Steps Up for Future Growth
Altimmune, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ ...
Altimmune's Pemvidutide: Strategic Implications for Regenerative ...
Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In ...
Can Altimmune's weight-loss drug be a game-changer? — TradingView News
Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive ...
Buy Altimmune's Potential Market Disruption With Pemvidutide (NASDAQ ...
Altimmune's Strategic Position in the MASH Space as Q4 Ends and 2026 ...
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor ...
Altimmune's Peptide-Based Therapies Offer Substantial Opportunity ...
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback ...
Altimmune's Stock Plummets Following Critical Short-Seller Analysis ...
Graviola Amazing: COVID-19 vaccine efficacy and effectiveness—the ...
